Literature DB >> 26033030

Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.

Evangelia Vlachodimitropoulou Koumoutsea1, Maciej Garbowski1, John Porter1.   

Abstract

Iron chelators are increasingly combined clinically but the optimal conditions for cellular iron mobilization and mechanisms of interaction are unclear. Speciation plots for iron(III) binding of paired combinations of the licensed iron chelators desferrioxamine (DFO), deferiprone (DFP) and deferasirox (DFX) suggest conditions under which chelators can combine as 'shuttle' and 'sink' molecules but this approach does not consider their relative access and interaction with cellular iron pools. To address this issue, a sensitive ferrozine-based detection system for intracellular iron removal from the human hepatocyte cell line (HuH-7) was developed. Antagonism, synergism or additivity with paired chelator combinations was distinguished using mathematical isobologram analysis over clinically relevant chelator concentrations. All combinations showed synergistic iron mobilization at 8 h with clinically achievable concentrations of sink and shuttle chelators. Greatest synergism was achieved by combining DFP with DFX, where about 60% of mobilized iron was attributable to synergistic interaction. These findings predict that the DFX dose required for a half-maximum effect can be reduced by 3·8-fold when only 1 μmol/l DFP is added. Mechanisms for the synergy are suggested by consideration of the iron-chelate speciation plots together with the size, charge and lipid solubilities for each chelator. Hydroxypyridinones with low lipid solubilities but otherwise similar properties to DFP were used to interrogate the mechanistic interactions of chelator pairs. These studies confirm that synergistic cellular iron mobilization requires one chelator to have the physicochemical properties to enter cells, chelate intracellular iron and subsequently donate iron to a second 'sink' chelator.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  combination chelation therapy; iron chelation; iron overload; isobologram; thalassaemia

Mesh:

Substances:

Year:  2015        PMID: 26033030     DOI: 10.1111/bjh.13512

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Increasing Intracellular Levels of Iron with Ferric Ammonium Citrate Leads to Reduced P-glycoprotein Expression in Human Immortalised Brain Microvascular Endothelial Cells.

Authors:  Stephanie A Newman; Yijun Pan; Jennifer L Short; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2021-02-02       Impact factor: 4.200

Review 2.  Oxidative Stress in β-Thalassemia.

Authors:  Eitan Fibach; Mutaz Dana
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

3.  Prescribing patterns and drug-related problems (DRPs) in transfusion-dependent paediatric thalassemia patients: A prospective interventional study from a tertiary care hospital in India.

Authors:  Tirin Babu; George Mathew Panachiyil; Juny Sebastian; Mandyam Dhati Ravi
Journal:  Int J Pediatr Adolesc Med       Date:  2020-01-07

Review 4.  Effectiveness and tolerability of twice daily dosing of deferasirox in unresponsive and intolerant transfusion-dependent beta-thalassemia patients: A narrative review.

Authors:  Tirin Babu; George Mathew Panachiyil; Juny Sebastian; Mandyam Dhati Ravi
Journal:  Indian J Pharmacol       Date:  2020 Nov-Dec       Impact factor: 1.200

5.  Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload.

Authors:  Raffaella Origa; Monia Cinus; Maria Paola Pilia; Barbara Gianesin; Antonietta Zappu; Valeria Orecchia; Maria Grazia Clemente; Carla Pitturru; Anna Rita Denotti; Francesco Corongiu; Simona Piras; Susanna Barella
Journal:  J Clin Med       Date:  2022-04-03       Impact factor: 4.241

6.  Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.

Authors:  Evangelia Vlachodimitropoulou; Yu-Lin Chen; Maciej Garbowski; Pimpisid Koonyosying; Bethan Psaila; Martha Sola-Visner; Nichola Cooper; Robert Hider; John Porter
Journal:  Blood       Date:  2017-09-01       Impact factor: 22.113

Review 7.  Pathophysiology and treatment of patients with beta-thalassemia - an update.

Authors:  Eitan Fibach; Eliezer A Rachmilewitz
Journal:  F1000Res       Date:  2017-12-20

8.  Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports.

Authors:  Lena H P Vroegindeweij; Agnita J W Boon; J H Paul Wilson; Janneke G Langendonk
Journal:  Orphanet J Rare Dis       Date:  2020-04-25       Impact factor: 4.123

9.  Pharmacological iron-chelation as an assisted nutritional immunity strategy against Piscirickettsia salmonis infection.

Authors:  Mario Caruffo; Dinka Mandakovic; Madelaine Mejías; Ignacio Chávez-Báez; Pablo Salgado; Daniela Ortiz; Liliana Montt; Javiera Pérez-Valenzuela; Francisca Vera-Tamargo; José Manuel Yánez; Jurij Wacyk; Rodrigo Pulgar
Journal:  Vet Res       Date:  2020-10-28       Impact factor: 3.683

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.